Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 110

1.

Translational Modeling in Schizophrenia: Predicting Human Dopamine D2 Receptor Occupancy.

Johnson M, Kozielska M, Pilla Reddy V, Vermeulen A, Barton HA, Grimwood S, de Greef R, Groothuis GM, Danhof M, Proost JH.

Pharm Res. 2016 Apr;33(4):1003-17. doi: 10.1007/s11095-015-1846-4. Epub 2015 Dec 30. Erratum in: Pharm Res. 2016 May;33(5):1305-6.

PMID:
26718955
2.

Dopamine D2 receptor occupancy as a predictor of catalepsy in rats: a pharmacokinetic-pharmacodynamic modeling approach.

Johnson M, Kozielska M, Pilla Reddy V, Vermeulen A, Barton HA, Grimwood S, de Greef R, Groothuis GM, Danhof M, Proost JH.

Pharm Res. 2014 Oct;31(10):2605-17. doi: 10.1007/s11095-014-1358-7. Epub 2014 May 3.

PMID:
24792824
3.

Dissociation between in vivo occupancy and functional antagonism of dopamine D2 receptors: comparing aripiprazole to other antipsychotics in animal models.

Natesan S, Reckless GE, Nobrega JN, Fletcher PJ, Kapur S.

Neuropsychopharmacology. 2006 Sep;31(9):1854-63. Epub 2005 Nov 30.

4.

Development of a population pharmacokinetic model to predict brain distribution and dopamine D2 receptor occupancy of raclopride in non-anesthetized rat.

Wong YC, Ilkova T, van Wijk RC, Hartman R, de Lange ECM.

Eur J Pharm Sci. 2018 Jan 1;111:514-525. doi: 10.1016/j.ejps.2017.10.031. Epub 2017 Nov 5.

5.

Mechanism-based pharmacokinetic-pharmacodynamic modeling of the dopamine D2 receptor occupancy of olanzapine in rats.

Johnson M, Kozielska M, Pilla Reddy V, Vermeulen A, Li C, Grimwood S, de Greef R, Groothuis GM, Danhof M, Proost JH.

Pharm Res. 2011 Oct;28(10):2490-504. doi: 10.1007/s11095-011-0477-7. Epub 2011 Jun 7.

6.

Using pharmacokinetic-pharmacodynamic modelling as a tool for prediction of therapeutic effective plasma levels of antipsychotics.

Olsen CK, Brennum LT, Kreilgaard M.

Eur J Pharmacol. 2008 Apr 28;584(2-3):318-27. doi: 10.1016/j.ejphar.2008.02.005. Epub 2008 Feb 12.

PMID:
18325493
7.

Dopamine D2 and D3 receptor occupancy in normal humans treated with the antipsychotic drug aripiprazole (OPC 14597): a study using positron emission tomography and [11C]raclopride.

Yokoi F, Gründer G, Biziere K, Stephane M, Dogan AS, Dannals RF, Ravert H, Suri A, Bramer S, Wong DF.

Neuropsychopharmacology. 2002 Aug;27(2):248-59.

8.

A pharmacodynamic modelling and simulation study identifying gender differences of daily olanzapine dose and dopamine D2-receptor occupancy.

Eugene AR, Masiak J.

Nord J Psychiatry. 2017 Aug;71(6):417-424. doi: 10.1080/08039488.2017.1314011. Epub 2017 May 9.

9.

Prediction of CNS occupancy of dopamine D2 receptor based on systemic exposure and in vitro experiments.

Kanamitsu K, Arakawa R, Sugiyama Y, Suhara T, Kusuhara H.

Drug Metab Pharmacokinet. 2016 Dec;31(6):395-404. doi: 10.1016/j.dmpk.2016.07.003. Epub 2016 Jul 30.

PMID:
27745731
10.

Amisulpride the 'atypical' atypical antipsychotic--comparison to haloperidol, risperidone and clozapine.

Natesan S, Reckless GE, Barlow KB, Nobrega JN, Kapur S.

Schizophr Res. 2008 Oct;105(1-3):224-35. doi: 10.1016/j.schres.2008.07.005. Epub 2008 Aug 16.

PMID:
18710798
11.

Exploration of optimal dosing regimens of haloperidol, a D2 Antagonist, via modeling and simulation analysis in a D2 receptor occupancy study.

Lim HS, Kim SJ, Noh YH, Lee BC, Jin SJ, Park HS, Kim S, Jang IJ, Kim SE.

Pharm Res. 2013 Mar;30(3):683-93. doi: 10.1007/s11095-012-0906-2. Epub 2012 Nov 10.

PMID:
23138261
12.

Striatal and extrastriatal dopamine D2 receptor occupancy by a novel antipsychotic, blonanserin: a PET study with [11C]raclopride and [11C]FLB 457 in schizophrenia.

Tateno A, Arakawa R, Okumura M, Fukuta H, Honjo K, Ishihara K, Nakamura H, Kumita S, Okubo Y.

J Clin Psychopharmacol. 2013 Apr;33(2):162-9. doi: 10.1097/JCP.0b013e3182825bce.

PMID:
23422369
14.

The role of striatal dopamine D2 receptors in the occurrence of extrapyramidal side effects: iodine-123-iodobenzamide single photon emission computed tomography study.

Corripio I, Ferreira A, Portella MJ, Pérez V, Escartí MJ, Del Valle Camacho M, Sauras RB, Alonso A, Grasa EM, Carrió I, Catafau AM, Alvarez E.

Psychiatry Res. 2012 Jan 30;201(1):73-7. doi: 10.1016/j.pscychresns.2011.02.004. Epub 2012 Jan 26.

PMID:
22281201
15.

Schizophrenia model of elevated D2(High) receptors: haloperidol reverses the amphetamine-induced elevation in dopamine D2(High).

Seeman P.

Schizophr Res. 2009 Apr;109(1-3):191-2. doi: 10.1016/j.schres.2008.12.024. Epub 2009 Jan 25. No abstract available.

PMID:
19171464
16.

Pharmacokinetic-pharmacodynamic modeling of the D₂ and 5-HT (2A) receptor occupancy of risperidone and paliperidone in rats.

Kozielska M, Johnson M, Pilla Reddy V, Vermeulen A, Li C, Grimwood S, de Greef R, Groothuis GM, Danhof M, Proost JH.

Pharm Res. 2012 Jul;29(7):1932-48. doi: 10.1007/s11095-012-0722-8. Epub 2012 Mar 22.

17.
18.

Acutely administered antipsychotic drugs are highly selective for dopamine D2 over D3 receptors.

McCormick PN, Wilson VS, Wilson AA, Remington GJ.

Pharmacol Res. 2013 Apr;70(1):66-71. doi: 10.1016/j.phrs.2013.01.002. Epub 2013 Jan 14.

PMID:
23327779
19.

Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia.

Kapur S, Zipursky R, Jones C, Remington G, Houle S.

Am J Psychiatry. 2000 Apr;157(4):514-20.

PMID:
10739409
20.

New Concepts in Dopamine D2 Receptor Biased Signaling and Implications for Schizophrenia Therapy.

Urs NM, Peterson SM, Caron MG.

Biol Psychiatry. 2017 Jan 1;81(1):78-85. doi: 10.1016/j.biopsych.2016.10.011. Epub 2016 Oct 19. Review.

Supplemental Content

Support Center